{"pmid":32438521,"title":"Update on clinical outcomes of women with COVID-19 during pregnancy.","text":["Update on clinical outcomes of women with COVID-19 during pregnancy.","Pregnant women have a disproportionately high risk of complications from other types of viral pneumonia; however, little is known about the full impact of coronavirus disease 2019 (COVID-19) in pregnancy. Pregnant women are uniquely susceptible to severe illnesses caused by viral infection, possibly due to the shift from cellular to humoral immunity during pregnancy and the puerperium [1].","Int J Gynaecol Obstet","Zeng, Yingchun","Lin, Lin","Yan, Qiaoyuan","Wei, Wei","Yang, Bing Xiang","Huang, Run","He, Fang","Chen, Dunjin","32438521"],"abstract":["Pregnant women have a disproportionately high risk of complications from other types of viral pneumonia; however, little is known about the full impact of coronavirus disease 2019 (COVID-19) in pregnancy. Pregnant women are uniquely susceptible to severe illnesses caused by viral infection, possibly due to the shift from cellular to humoral immunity during pregnancy and the puerperium [1]."],"journal":"Int J Gynaecol Obstet","authors":["Zeng, Yingchun","Lin, Lin","Yan, Qiaoyuan","Wei, Wei","Yang, Bing Xiang","Huang, Run","He, Fang","Chen, Dunjin"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438521","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/ijgo.13236","keywords":["covid-19","china","clinical outcomes","coronavirus","pregnancy"],"topics":["Treatment"],"weight":1,"_version_":1667521393702469635,"score":9.490897,"similar":[{"pmid":32498581,"title":"Relationship between pregnancy and coronavirus: what we know.","text":["Relationship between pregnancy and coronavirus: what we know.","The identification in China in December 2019 of a new coronavirus (SARS-CoV-2) immediately rekindled the spotlight on a problem also addressed in the past during the epidemics of SARS in 2002-2003 and MERS in 2012: the implications of a possible infection during pregnancy, both for pregnant women and for fetuses and infants. Pregnancy is characterized by some changes involving both the immune system and the pulmonary physiology, exposing the pregnant woman to a greater susceptibility to viral infections and more serious complications. The objective of this review is therefore to analyze the relationship between pregnancy and known coronaviruses, with particular reference to SARS-CoV-2.","J Matern Fetal Neonatal Med","Forestieri, Stefano","Marcialis, Maria Antonietta","Migliore, Lucia","Panisi, Cristina","Fanos, Vassilios","32498581"],"abstract":["The identification in China in December 2019 of a new coronavirus (SARS-CoV-2) immediately rekindled the spotlight on a problem also addressed in the past during the epidemics of SARS in 2002-2003 and MERS in 2012: the implications of a possible infection during pregnancy, both for pregnant women and for fetuses and infants. Pregnancy is characterized by some changes involving both the immune system and the pulmonary physiology, exposing the pregnant woman to a greater susceptibility to viral infections and more serious complications. The objective of this review is therefore to analyze the relationship between pregnancy and known coronaviruses, with particular reference to SARS-CoV-2."],"journal":"J Matern Fetal Neonatal Med","authors":["Forestieri, Stefano","Marcialis, Maria Antonietta","Migliore, Lucia","Panisi, Cristina","Fanos, Vassilios"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498581","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/14767058.2020.1771692","keywords":["covid-19","sars-cov-2","coronavirus","pregnancy"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1668804508664201216,"score":217.04906},{"pmid":32350871,"title":"Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic.","text":["Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic.","OBJECTIVE: To study vaginal delivery outcomes and neonatal prognosis and summarize the management of vaginal delivery during the COVID-19 pandemic. METHODS: A retrospective analysis of medical records and comparison of vaginal delivery outcomes between 10 pregnant women with clinical diagnosis of COVID-19 and 53 pregnant women without COVID-19 admitted to Zhongnan Hospital of Wuhan University between January 20 and March 2, 2020. Results of laboratory tests, imaging tests, and SARS-CoV-2 nucleic acid tests were also analyzed in neonates delivered by pregnant women with clinical diagnosis of COVID-19. RESULTS: There were no significant differences in gestational age, postpartum hemorrhage, and perineal resection rates between the two groups. There were no significant differences in birth weight of neonates and neonatal asphyxia rates between the two groups. Neonates delivered by pregnant women with clinical diagnosis of COVID-19 tested negative for SARS-CoV-2 infection. CONCLUSIONS: Under the premise of full evaluation of vaginal delivery conditions and strict protection measures, pregnant women with ordinary type COVID-19 can try vaginal delivery without exacerbation of COVID-19 and without increasing the risk of SARS-CoV-2 infection in neonates.","Int J Gynaecol Obstet","Liao, Jing","He, Xiaoyan","Gong, Qing","Yang, Lingyun","Zhou, Chunhua","Li, Jiafu","32350871"],"abstract":["OBJECTIVE: To study vaginal delivery outcomes and neonatal prognosis and summarize the management of vaginal delivery during the COVID-19 pandemic. METHODS: A retrospective analysis of medical records and comparison of vaginal delivery outcomes between 10 pregnant women with clinical diagnosis of COVID-19 and 53 pregnant women without COVID-19 admitted to Zhongnan Hospital of Wuhan University between January 20 and March 2, 2020. Results of laboratory tests, imaging tests, and SARS-CoV-2 nucleic acid tests were also analyzed in neonates delivered by pregnant women with clinical diagnosis of COVID-19. RESULTS: There were no significant differences in gestational age, postpartum hemorrhage, and perineal resection rates between the two groups. There were no significant differences in birth weight of neonates and neonatal asphyxia rates between the two groups. Neonates delivered by pregnant women with clinical diagnosis of COVID-19 tested negative for SARS-CoV-2 infection. CONCLUSIONS: Under the premise of full evaluation of vaginal delivery conditions and strict protection measures, pregnant women with ordinary type COVID-19 can try vaginal delivery without exacerbation of COVID-19 and without increasing the risk of SARS-CoV-2 infection in neonates."],"journal":"Int J Gynaecol Obstet","authors":["Liao, Jing","He, Xiaoyan","Gong, Qing","Yang, Lingyun","Zhou, Chunhua","Li, Jiafu"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350871","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/ijgo.13188","keywords":["covid-19","china","management","neonatal outcome","pregnancy","vaginal delivery"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Diagnosis","Transmission"],"weight":1,"_version_":1666138495633063938,"score":208.74146},{"pmid":32145714,"title":"[Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province].","text":["[Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province].","Objective: To study the effect of COVID-19 on pregnancy outcomes and neonatal prognosis in Hubei Province. Methods: A retrospective comparison of the pregnancy outcomes was done between 16 women with COVID-19 and 45 women without COVID-19. Also, the results of laboratory tests, imaging examinations, and the 2019-nCoV nucleic acid test were performed in 10 cases of neonatal deliverd from women with COVID-19. Results: (1) Of the 16 pregnant women with COVID-19, 15 cases were ordinary type and 1 case was severe type. No one has progressed to critical pneumonia. The delivery method of the two groups was cesarean section, and the gestational age were (38.7+/-1.4) and (37.9+/-1.6) weeks, there was no significant difference between the two groups (P> 0.05). Also, there wee no significant differences in the intraoperative blood loss and birth weight of the newborn between the two groups (all P>0.05). (2) Ten cases of neonates delivered from pregnant women with COVID-19 were collected. The 2019-nCoV nucleic acid test were all negative. There were no significant differences in fetal distress, meconium-stained amniotic fluid, preterm birth, and neonatal asphyxia between the two groups (all P>0.05). (3) In the treatment of uterine contraction fatigue, carbetocin or carboprost tromethamine was used more in cesarean section for pregnant women with COVID-19 (1.3+/-0.6), compared with Non-COVID-19 group (0.5+/-0.7), the difference was statistically significant (P=0.001). Conclusions: If there is an indication for obstetric surgery or critical illness of COVID-19 in pregnant women, timely termination of pregnancy will not increase the risk of premature birth and asphyxia of the newborn, but it is beneficial to the treatment and rehabilitation of maternal pneumonia. Preventive use of long-acting uterotonic agents could reduce the incidence of postpartum hemorrhage during surgery. 2019-nCoV infection has not been found in neonates deliverd from pregnant women with COVID-19.","Zhonghua Fu Chan Ke Za Zhi","Zhang, L","Jiang, Y","Wei, M","Cheng, B H","Zhou, X C","Li, J","Tian, J H","Dong, L","Hu, R H","32145714"],"abstract":["Objective: To study the effect of COVID-19 on pregnancy outcomes and neonatal prognosis in Hubei Province. Methods: A retrospective comparison of the pregnancy outcomes was done between 16 women with COVID-19 and 45 women without COVID-19. Also, the results of laboratory tests, imaging examinations, and the 2019-nCoV nucleic acid test were performed in 10 cases of neonatal deliverd from women with COVID-19. Results: (1) Of the 16 pregnant women with COVID-19, 15 cases were ordinary type and 1 case was severe type. No one has progressed to critical pneumonia. The delivery method of the two groups was cesarean section, and the gestational age were (38.7+/-1.4) and (37.9+/-1.6) weeks, there was no significant difference between the two groups (P> 0.05). Also, there wee no significant differences in the intraoperative blood loss and birth weight of the newborn between the two groups (all P>0.05). (2) Ten cases of neonates delivered from pregnant women with COVID-19 were collected. The 2019-nCoV nucleic acid test were all negative. There were no significant differences in fetal distress, meconium-stained amniotic fluid, preterm birth, and neonatal asphyxia between the two groups (all P>0.05). (3) In the treatment of uterine contraction fatigue, carbetocin or carboprost tromethamine was used more in cesarean section for pregnant women with COVID-19 (1.3+/-0.6), compared with Non-COVID-19 group (0.5+/-0.7), the difference was statistically significant (P=0.001). Conclusions: If there is an indication for obstetric surgery or critical illness of COVID-19 in pregnant women, timely termination of pregnancy will not increase the risk of premature birth and asphyxia of the newborn, but it is beneficial to the treatment and rehabilitation of maternal pneumonia. Preventive use of long-acting uterotonic agents could reduce the incidence of postpartum hemorrhage during surgery. 2019-nCoV infection has not been found in neonates deliverd from pregnant women with COVID-19."],"journal":"Zhonghua Fu Chan Ke Za Zhi","authors":["Zhang, L","Jiang, Y","Wei, M","Cheng, B H","Zhou, X C","Li, J","Tian, J H","Dong, L","Hu, R H"],"date":"2020-03-09T11:00:00Z","year":2020,"_id":"32145714","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.cn112141-20200218-00111","keywords":["2019-ncov","covid-19","neonates","pneumonia","pregnancy outcomes"],"locations":["Hubei","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["carbetocin","carboprost tromethamine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490680639489,"score":196.73201},{"pmid":32328850,"pmcid":"PMC7178925","title":"Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.","text":["Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.","To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future.","Eur J Clin Microbiol Infect Dis","Zhao, Xiaoxuan","Jiang, Yuepeng","Zhao, Yang","Xi, Hongyan","Liu, Chang","Qu, Fan","Feng, Xiaoling","32328850"],"abstract":["To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future."],"journal":"Eur J Clin Microbiol Infect Dis","authors":["Zhao, Xiaoxuan","Jiang, Yuepeng","Zhao, Yang","Xi, Hongyan","Liu, Chang","Qu, Fan","Feng, Xiaoling"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328850","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s10096-020-03897-6","keywords":["antiviral treatment","fetal safety","new coronavirus disease","pregnancy","virus susceptibility"],"e_drugs":["Metformin","Chloroquine","Glycyrrhizic Acid"],"topics":["Treatment"],"weight":1,"_version_":1666138494632722434,"score":191.9435},{"pmid":32217113,"title":"Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.","text":["Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.","The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally at an accelerated rate, with a basic reproduction number (R0) of 2-2.5, indicating that 2-3 persons will be infected from an index patient. A serious public health emergency, it is particularly deadly in vulnerable populations and communities in which healthcare providers are insufficiently prepared to manage the infection. As of March 16, 2020, there are more than 180,000 confirmed cases of COVID-19 worldwide, with more than 7000 related deaths. The SARS-CoV-2 virus has been isolated from asymptomatic individuals, and affected patients continue to be infectious 2 weeks after cessation of symptoms. The substantial morbidity and socioeconomic impact have necessitated drastic measures across all continents, including nationwide lockdowns and border closures. Pregnant women and their fetuses represent a high-risk population during infectious disease outbreaks. To date, the outcomes of 55 pregnant women infected with COVID-19 and 46 neonates have been reported in the literature, with no definite evidence of vertical transmission. Physiological and mechanical changes in pregnancy increase susceptibility to infections in general, particularly when the cardiorespiratory system is affected, and encourage rapid progression to respiratory failure in the gravida. Furthermore, the pregnancy bias toward T-helper 2 (Th2) system dominance, which protects the fetus, leaves the mother vulnerable to viral infections, which are more effectively contained by the Th1 system. These unique challenges mandate an integrated approach to pregnancies affected by SARS-CoV-2. Here we present a review of COVID-19 in pregnancy, bringing together the various factors integral to the understanding of pathophysiology and susceptibility, diagnostic challenges with real-time reverse transcription polymerase chain reaction (RT-PCR) assays, therapeutic controversies, intrauterine transmission, and maternal-fetal complications. We discuss the latest options in antiviral therapy and vaccine development, including the novel use of chloroquine in the management of COVID-19. Fetal surveillance, in view of the predisposition to growth restriction and special considerations during labor and delivery, is addressed. In addition, we focus on keeping frontline obstetric care providers safe while continuing to provide essential services. Our clinical service model is built around the principles of workplace segregation, responsible social distancing, containment of cross-infection to healthcare providers, judicious use of personal protective equipment, and telemedicine. Our aim is to share a framework that can be adopted by tertiary maternity units managing pregnant women in the flux of a pandemic while maintaining the safety of the patient and healthcare provider at its core.","Am J Obstet Gynecol","Dashraath, Pradip","Wong, Jing Lin Jeslyn","Lim, Mei Xian Karen","Lim, Li Min","Li, Sarah","Biswas, Arijit","Choolani, Mahesh","Mattar, Citra","Su, Lin Lin","32217113"],"abstract":["The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally at an accelerated rate, with a basic reproduction number (R0) of 2-2.5, indicating that 2-3 persons will be infected from an index patient. A serious public health emergency, it is particularly deadly in vulnerable populations and communities in which healthcare providers are insufficiently prepared to manage the infection. As of March 16, 2020, there are more than 180,000 confirmed cases of COVID-19 worldwide, with more than 7000 related deaths. The SARS-CoV-2 virus has been isolated from asymptomatic individuals, and affected patients continue to be infectious 2 weeks after cessation of symptoms. The substantial morbidity and socioeconomic impact have necessitated drastic measures across all continents, including nationwide lockdowns and border closures. Pregnant women and their fetuses represent a high-risk population during infectious disease outbreaks. To date, the outcomes of 55 pregnant women infected with COVID-19 and 46 neonates have been reported in the literature, with no definite evidence of vertical transmission. Physiological and mechanical changes in pregnancy increase susceptibility to infections in general, particularly when the cardiorespiratory system is affected, and encourage rapid progression to respiratory failure in the gravida. Furthermore, the pregnancy bias toward T-helper 2 (Th2) system dominance, which protects the fetus, leaves the mother vulnerable to viral infections, which are more effectively contained by the Th1 system. These unique challenges mandate an integrated approach to pregnancies affected by SARS-CoV-2. Here we present a review of COVID-19 in pregnancy, bringing together the various factors integral to the understanding of pathophysiology and susceptibility, diagnostic challenges with real-time reverse transcription polymerase chain reaction (RT-PCR) assays, therapeutic controversies, intrauterine transmission, and maternal-fetal complications. We discuss the latest options in antiviral therapy and vaccine development, including the novel use of chloroquine in the management of COVID-19. Fetal surveillance, in view of the predisposition to growth restriction and special considerations during labor and delivery, is addressed. In addition, we focus on keeping frontline obstetric care providers safe while continuing to provide essential services. Our clinical service model is built around the principles of workplace segregation, responsible social distancing, containment of cross-infection to healthcare providers, judicious use of personal protective equipment, and telemedicine. Our aim is to share a framework that can be adopted by tertiary maternity units managing pregnant women in the flux of a pandemic while maintaining the safety of the patient and healthcare provider at its core."],"journal":"Am J Obstet Gynecol","authors":["Dashraath, Pradip","Wong, Jing Lin Jeslyn","Lim, Mei Xian Karen","Lim, Li Min","Li, Sarah","Biswas, Arijit","Choolani, Mahesh","Mattar, Citra","Su, Lin Lin"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217113","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ajog.2020.03.021","keywords":["covid-19","mers-cov,morbidity","sars-cov","sars-cov-2","antiviral","baricitinib","chloroquine","coronavirus","fever","mask","mortality","obstetric management","pandemic","pregnancy","remdesivir","respiratory distress syndrome","respiratory failure","sepsis","susceptibility","virus"],"e_drugs":["Chloroquine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138492294397954,"score":183.31921}]}